FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

Tudriqev is a genetically modified oncolytic virus designed to selectively replicate in and destroy tumor cells while stimulating an immune response. The accelerated approval pathway reflects the therapy's promise for patients with advanced melanoma who have exhausted other options. While specific efficacy data were not detailed in the announcement, accelerated approvals are based on surrogate endpoints like tumor response, with continued approval contingent on confirmatory trials. This marks another step forward in the growing field of viral immunotherapies for cancer, following earlier agents like T-VEC. The approval underscores the FDA's commitment to expediting novel treatments for serious, refractory malignancies.